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Serum Adiponectin Levels Are an Independent Predictor of the Extent
of Coronary Artery Disease in Men
To the Editor: Several risk factors for the development of coronary
artery disease (CAD) have been identified, correlating with the
incidence and progression of atherosclerotic disease. Low adiponectin,
an adipocytokine, appears to be a clinically important mediator of
atherosclerosis. Thus, prospective studies have shown that elevated
adiponectin levels predicted a decreased risk of myocardial infarction
in the general population and among patients with type 2 diabetes
(T2D) (1,2). No study to date has combined serum adiponectin levels
and polymorphisms with an influence on adiponectin levels to
investigate the potential association of adiponectin with the extent of
coronary atherosclerosis as measured by several defined angiographic
scores. We therefore investigated the relation of serum adiponectin to
the extent of CAD with the help of two established scores: “severity
score” (SS) and “extent score” (ES) (3,4).
Figure 1. (A) Thrombolysis In Myocardial Infarction myocardial perfusion (TMP) grade by the presence or absence of right bundle branch block (RBBB)
in 105 patients with ST-segment elevation myocardial infarction (STEMI). (B) Myocardial tissue-level reperfusion by the presence or absence of RBBB
in 105 patients with STEMI.
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Two hundred forty-seven individuals, ages 31 to 83 years, who
were undergoing clinically indicated coronary angiography at the
University Hospital Heidelberg were enrolled. Treatment with per-
oxisome proliferator-activated receptor (PPAR)-alpha or PPAR-
gamma agonists, known to affect adiponectin levels, was an exclusion
criterion. Serum samples were obtained before angiography and
frozen at 70°C until analyses were performed. Serum adiponectin
was determined by enzyme-linked immunosorbent assay (B-
Bridge-International, San Jose, California). The extent of angio-
graphically documented CAD was quantified by two independent
investigators as follows: 1) the SS as one-vessel, two-vessel, or
three-vessel disease, defined as stenosis of more than 50% of the
luminal diameter (3); and 2) the ES, in which atherosclerotic wall
irregularities in 10 defined segments of the coronary arteries were
evaluated (4). Two-tailed bivariate correlations were determined
by the Spearman correlation coefficient, and comparisons between
two sets of patients were performed with the Mann-Whitney U
test. Comparisons between quartiles (SS) and quintiles (ES) were
performed with the Kruskal-Wallis test. The study was approved
by the ethics committee of Heidelberg University. All patients gave
written informed consent.
Coronary artery disease was found in 172 patients. Compared
with the 75 patients without CAD, the 172 men with CAD were
older, more likely to be a current smoker, and had higher blood
pressure and lower high-density lipoprotein cholesterol (data not
shown). Adiponectin levels were significantly lower in patients
with CAD than in those without (4.8 vs. 7.5 g/ml; p  0.001).
The severity of CAD as quantified by SS correlated significantly
with serum adiponectin (p  0.001 by Kruskal-Wallis test)
(Fig. 1A). In addition to severity of CAD, we further found a
significant inverse correlation between serum adiponectin and the
more sensitive ES (r  0.23; p  0.001). When patients were
divided into quintiles of increasing ES, a stepwise decrease in
adiponectin levels was associated with increasing extent of atheroscle-
rotic wall irregularities (p  0.001 by Kruskal-Wallis test) (Fig. 1B).
Multivariate regression models were used to estimate the partial
association between serum adiponectin and the extent of CAD. In the
first model, adjusted for age and body mass index, adiponectin was a
significant and independent predictor of both SS and ES (Table 1,
Model 1). When traditional cardiovascular risk factors entered the
regression analysis (Table 1, Model 2) and, finally, markers of
systemic inflammation (Table 1, Model 3) were added, adiponectin
remained an independent predictive factor for the extent of CAD in
both scores. This result was unaffected by the current medication of
the study population.
To investigate potential associations between genetic determi-
nations of serum adiponectin and the extent of CAD, we further
screened for two genetic variations known to influence adiponectin
expression: a silent mutation in exon-2 of the adiponectin gene
(T94G) (5) and a polymorphism in exon B of the PPAR-gamma-2
gene (Pro12Ala) associated with decreased serum adiponectin (6).
The allele frequencies of the PPAR-gamma-2–Pro12Ala and
adiponectin-T94G substitution were 0.214 and 0.173, respectively.
Both polymorphisms were in genetic equilibrium according to the
Hardy-Weinberg law, and the PPAR-gamma-2 polymorphism was
not in linkage disequilibrium with the adiponectin polymorphism.
Serum adiponectin was lower among patients with PPAR-
gamma-2–Pro12Ala (Ala-allele: 3.9 0.4g/ml vs. Pro-allele: 5.9
0.4 g/ml; p  0.001) and was increased in patients with
adiponectin-T94G (G-allele: 7.6 0.6 g/ml vs. T-allele: 5.1 0.5
g/ml; p  0.001). Moreover, patients with PPAR-gamma-2–
Pro12Ala showed increased CAD in ES (Ala-allele: 34.4  4.0 vs.
Figure 1. Associations between serum adiponectin levels and coronary artery disease (CAD) in men. The central line represents the median, the boxes span
from the 25th to 75th percentiles, and the error bars extend from the 10th to 90th percentiles. (A) A stepwise decrease in adiponectin levels was associated
with the number of50% stenosed vessels (severity score). VD vessel disease. (B) A stepwise decrease in adiponectin levels was associated with the extent
of atherosclerotic wall irregularities (extent score).
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Pro-allele: 26.0 2.7; p 0.03) and a tendency toward increased CAD
in SS (Ala-allele: 1.60  0.19 vs. Pro-allele: 1.34 0.09; p  0.09).
Patients with the adiponectin-T94G variant had significantly less
CAD in both angiographic scores: ES (G-allele: 21.9  3.1 vs.
T-allele: 30.7  2.3; p  0.03) and SS (G-allele: 1.02  0.14 vs.
T-allele: 1.53  0.10; p  0.01). In an additional linear regression
analysis with SS or ES as dependent variable, only adiponectin
remained a significant predictor of CAD, with the two polymor-
phisms being inter-correlated with adiponectin (data not shown).
In summary, these data demonstrate that serum adiponectin levels
and the extent of CAD show a significant correlation in men. These
results were obtained with two established scores of which the ES in
particular has been demonstrated to better correlate with cardiovas-
cular risk factors than other scores (4). Furthermore, we demonstrate
that genetic variations known to affect adiponectin levels were signif-
icantly associated with the extent of CAD. This is in accordance with
a recent study reporting a genetic variability of the adiponectin gene
(G276T) to be associated with a reduced cardiovascular risk in
patients with T2D (7). Our results indicate that the measurement of
serum adiponectin might represent a novel diagnostic tool to stratify
patients at risk for CAD and to identify those patients who would
benefit most from preventive strategies.
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